A chemical that temporarily restores some vision to blind mice has been discovered.聽 Its discoverers are working on聽 an聽 improved compound that may someday allow people with degenerative blindness to see again.
Read the聽in Neuron
聽on earlier study
A team of UW Medicine researchers, in collaboration with scientists at the University of California, Berkeley, and the University of Munich, conducted the study. Their findings appear in the July 26th聽issue of the journal聽Neuron.
The approach could eventually help those with retinitis pigmentosa, a genetic disease that is the most common inherited form of blindness, as well as age-related macular degeneration, the most common cause of acquired blindness in the developed world. In both diseases, the light sensitive cells in the retina 鈥� the rods and cones 鈥� die, leaving the eye without functional photoreceptors.
鈥淭his is a major advance in the field of vision restoration,鈥� said co-author Dr. Russell Van Gelder, chair of the Department of Ophthalmology at the UW School of Medicine.
The chemical, called AAQ, acts by making the remaining, normally 鈥渂lind鈥� cells in the retina sensitive to light, said lead researcher Richard Kramer, UC Berkeley professor of molecular and cell biology. AAQ is a photoswitch that binds to protein ion channels on the surface of retinal cells. When switched on by light, AAQ alters the flow of ions through the channels and activates these neurons much the way rods and cones are activated by light.
鈥淭his is similar to the way local anesthetics work: they embed themselves in ion channels and stick around for a long time, so that you stay numb for a long time,鈥� Kramer said. 鈥淥ur molecule is different in that it鈥檚 light sensitive, so you can turn it on and off and turn on or off neural activity.鈥�
Because the chemical eventually wears off, it may offer a safer alternative to other experimental approaches for restoring sight, such as gene or stem cell therapies, which permanently change the retina. It is also less invasive than implanting light-sensitive chips in the eye.
鈥淭he photoswitch approach offers real hope to patients with retinal degeneration,鈥� Van Gelder said. 鈥淲e still need to show that these compounds are safe and will work in people the way they work in mice, but these results demonstrate that this class of compound restores light sensitivity to retinas blind from genetic disease.鈥�
The blind mice in the experiment had genetic mutations that made their rods and cones die within months of birth and inactivated other photopigments in the eye. After injecting very small amounts of AAQ into the eyes of the blind mice, Van Gelder and his colleagues confirmed that they had restored light sensitivity because the mice鈥檚 pupils contracted in bright light, and the mice showed light avoidance, a typical rodent behavior impossible without the animals being able to see some light. The team is hoping to conduct more sophisticated vision tests in rodents injected with the next generation of the compound.
鈥淭he advantage of this approach is that it is a simple chemical, which means that you can change the dosage, you can use it in combination with other therapies, or you can discontinue the therapy if you don鈥檛 like the results. As improved chemicals become available, you could offer them to patients. You can鈥檛 do that when you surgically implant a chip or after you genetically modify somebody,鈥� Kramer said.
From optogenetics to implanted chips
The current technologies being evaluated for restoring sight to people whose rods and cones have died include injection of stem cells to regenerate the rods and cones; 鈥渙ptogenetics,鈥� that is, gene therapy to insert a photoreceptor gene into blind neurons to make them sensitive to light; and installation of electronic prosthetic devices, such as a small light-sensitive retinal chip with electrodes that stimulate blind neurons. Several dozen people already have retinal implants and have had rudimentary, low vision restored, Kramer said.
Eight years ago, Kramer, Trauner, a former UC Berkeley chemist now at the University of Munich, and their colleagues developed an optogenetic technique to chemically alter potassium ion channels in blind neurons so that a photoswitch could latch on. Potassium channels normally open to turn a cell off, but with the attached photoswitch, they were opened when hit by ultraviolet light and closed when hit by green light, thereby activating and deactivating the neurons.
Subsequently, Trauner synthesized AAQ (acrylamide-azobenzene-quaternary ammonium), a photoswitch that attaches to potassium channels without the need to genetically modify the channel. Tests of this compound are reported in the current聽Neuron听辫补辫别谤.
New versions of AAQ now being tested are better, Kramer said. They activate neurons for days rather than hours using blue-green light of moderate intensity, and these photoswitches naturally deactivate in darkness, so that a second color of light is not needed to switch them off.
Coauthors with Van Gelder, Kramer and Trauner are post-doctoral fellow Joseph Nemargut and ophthalmology resident Yivgeny Sychev at the 天美影视传媒; and UC Berkeley graduate students Aleksandra Polosukhina, Jeffrey Litt, Ivan Tochitsky, Ivan De Kouchkovsky, Tracy Huang and Katharine Borges. The work was supported by the National Eye Institute of the National Institutes of Health (EY018957 & EY003176) and Research to Prevent Blindness.